The global Fecal Calprotectin Test Market was valued at USD 126.9 million in 2022 and is projected to surpass USD 355.8 million by the end of 2031. The market is expected to expand at a CAGR of 10.7% from 2023 to 2031, driven by the rising prevalence of inflammatory bowel diseases (IBD), growing awareness about non-invasive diagnostic testing, and increasing demand for early detection of gastrointestinal disorders. Advancements in diagnostic technologies, expanding healthcare infrastructure, and the growing adoption of fecal biomarker testing are further supporting the strong growth of the market worldwide.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78383

The global fecal calprotectin test market is expected to witness significant growth in the next few years due to rise in prevalence of inflammatory bowel disease (IBD) and gastrointestinal disorders. Fecal calprotectin test is most commonly used in adult patients due to high incidence rate of inflammatory bowel disease (IBD) and colorectal cancer among these patients. Increase in awareness among patients and healthcare professionals about the benefits of early diagnosis and treatment is expected to drive global fecal calprotectin test market growth.

Development of more accurate and low cost fecal calprotectin tests offers lucrative opportunities to market players. Companies are focusing on developing cost-efficient and more precise tests in order to increase market share and revenue. However, high cost of tests and lack of reimbursement policies in some regions are likely to hamper market growth.

Key Findings of the Market Report

• Triage Efficiency: Fecal calprotectin is now the primary tool for excluding IBD in symptomatic patients, reducing unnecessary colonoscopies by an estimated 35% to 50% in participating health systems.
• Segment Dominance: The IBD Indication remains the undisputed market leader, though Colorectal Cancer (CRC) screening is gaining traction as a complementary marker for inflammation.
• Assay Evolution: While ELISA is the revenue leader, Lateral Flow/POC tests are seeing a 25% increase in adoption for routine monitoring.
• Home-Testing Demand: Demand for at-home sample collection has risen by over 42% since 2024, reflecting a clear patient preference for privacy and convenience.

Global Market: Growth Drivers

• Rising Global IBD Burden: Modern lifestyles and processed diets have led to a "second wave" of IBD cases in emerging economies, expanding the target patient pool.
• Non-Invasive Diagnostic Preference: Approximately 68% of patients now actively request non-invasive alternatives to endoscopy, pressuring providers to adopt biomarker testing.
• Digital Health Synergy: Integration with telehealth platforms and AI-driven diagnostic apps has made the ordering and interpretation of these tests more seamless.
• Preventive Healthcare Initiatives: Government-led screening programs for GI diseases are increasingly including calprotectin as a baseline diagnostic criterion.

Global Market: Key Players

The market is characterized by a mix of specialized diagnostic manufacturers and massive medical technology conglomerates.

• BÜHLMANN Laboratories AG (Widely regarded as the market leader in calprotectin assay precision)
• Thermo Fisher Scientific Inc.
• DiaSorin S.p.A.
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories
• QuidelOrtho Corporation
• Svar Life Science AB
• Eurofins Scientific
• Beckman Coulter (Danaher Corporation)
• Meridian Bioscience, Inc.

Global Market: Segmentation

By Assay Type

• ELISA: High-sensitivity, high-throughput; used primarily in large reference labs.
• Point-of-Care (POC) / Rapid Tests: Used in clinics and at home for quick screening (Fastest growth).
• Enzyme Fluoroimmunoassay (EFIA): Utilized for specialized, high-precision quantitative analysis.

By Indication

• Inflammatory Bowel Disease (IBD): Includes Crohn's Disease and Ulcerative Colitis (Dominant segment).
• Irritable Bowel Syndrome (IBS): Used as a negative-screen to rule out organic inflammation.
• Colorectal Cancer: Used as a secondary biomarker for early tissue inflammation.
• Celiac Disease: Growing application in pediatric GI monitoring.

By End-User

• Hospitals & Clinics: Account for the majority of initial diagnostic testing.
• Diagnostic Laboratories: Hubs for high-volume routine monitoring and complex assays.
• Academic & Research Institutes: Focus on longitudinal studies of IBD and new biomarker validation.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=78383&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com 
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com